Human medicines European public assessment report (EPAR): Iclusig, ponatinib, Date of authorisation: 01/07/2013, Revision: 27, Status: Authorised

The updated EPAR for Iclusig (ponatinib) signifies a treatment advancement for adults with specific types of leukaemia, offering a viable option for those resistant or intolerant to other tyrosine kinase inhibitors. The inclusion of dose optimization and efficacy against the T315I mutation provides clinicians with valuable insights for personalized treatment strategies.